WHAT IS CLAIMED IS:

1. A method of preventing or treating rejection of a grafted cell, tissue, or organ in a mammal comprising administering to the mammal a composition comprising a purified complex consisting essentially of a heat shock protein noncovalently bound to an antigenic molecule.

2. The method of Claim 1, wherein the heat shock protein is not an alloantigen of the grafted cells, tissue, or organ.

3. The method of Claim 1, wherein the antigenic molecule is not an alloantigen of the grafted cells, tissue, or organ.

4. A method of treating rejection of a grafted cell, tissue, or organ in a mammal comprising administering to the mammal a composition comprising a purified heat shock protein which is substantially free of complexed antigenic molecule, wherein the heat shock protein is not cpn10.

5. The method of Claim 4, wherein the heat shock protein is not an alloantigen of the grafted cells, tissue, or organ.

6. The method of Claim 1 or 4, wherein the grafted cell, tissue, or organ is skin, liver, kidney, heart, bone marrow, pancreas, lung, cornea, cartilage, or a cell derived therefrom.

7. The method of Claim 6, wherein the grafted cell or tissue is skin or a cell derived from skin.

8. The method of Claim 1 or 4, wherein the heat shock protein is mammalian.

9. The method of Claim 8, wherein the heat shock protein is human.

10. The method of Claim 8, wherein the heat shock protein is gp96.

11. The method of Claim 8, wherein the heat shock protein is hsp70.

12. The method of Claim 8, wherein the heat shock protein is hsp90.

~~13. The method of Claim 1, 2, 3, 4, or 5, wherein the~~ mammal is human.

14. The method of Claim 1 or 4, comprising administering the heat shock protein before the cell, tissue, or organ is grafted.

15. The method of Claim 1 or 4, comprising administering the heat shock protein after the cell, tissue, or organ is grafted.

16. The method of Claim 1 or 4, wherein the amount of the heat shock protein present in the composition is in a range of 5 μg to 5,000 μg.

17. The method of Claim 1 or 4, wherein the amount of the heat shock protein present in the composition is 100 μg or more.

18. The method of Claim 1 or 4, wherein the amount of ~~the heat shock protein present in the composition is 200 μg or more.~~

19. The method of Claim 14, further comprising administering to the mammal a sample of cells or tissue obtained from the cell, tissue, or organ donor prior to administration of the heat shock protein.

~~20. The method of Claim~~ 1 or 4, wherein the heat shock ~~protein is not hsp60.~~

~~21. The method of Claim 1, wherein the antigenic molecule is not a bacterial peptide.~~

~~22.~~ A kit for use in ~~treating rejection of a grafted~~ cell, tissue, or organ comprising in a container a composition comprising a purified complex consisting essentially of a heat shock protein noncovalently bound to an antigenic molecule, and a composition comprising an immunosuppressive agent.

23. The kit of Claim 22, wherein the heat shock protein is not an alloantigen of the grafted tissue.

24. The kit of Claim 22, wherein the antigenic molecule is not an alloantigen of the grafted tissue.

~~25.~~ A kit for use in treating rejection of a grafted cell, tissue, or organ in a mammal comprising in a container a composition comprising a purified heat shock protein which is substantially free of complexed antigenic molecule, wherein the heat shock protein is not cpn10, and a composition comprising an immunosuppressive agent.

26. The kit of Claim 25, wherein the heat shock protein is not an antigen of the grafted tissue or organ.

27. The kit of Claim 22, 23, 24, 25, or 26, wherein the heat shock protein is gp96, hsp70, or hsp90.

28. The kit of Claim 22 or 25, wherein the grafted tissue is skin.

29. The kit of Claim 22 or 25, wherein the heat shock protein is gp96, hsp70, or hsp90.

~~29.~~ The kit of Claim 22 or 25, wherein the amount of the heat shock protein present in the container is in a range of ~~10~~μg to 500μg.

30. The kit of Claim 22 or 25, wherein the amount of the heat shock protein present in the container is in a range of at least 100 μg.

31. The kit of Claim 22 or 25, wherein the immunosuppressive agent is selected from the group consisting of cyclosporine, azathioprine, mycophenolate mofetil, tacrolimus, corticosteroids, prednisone, cyclophosphamide, antilymphocyte globulin (ALG), antithymocyte globulin (ATG), and orthoclone OKT3.

add a7